エピジェネティクスの世界市場規模：製品タイプ別、用途別、エンドユーザー別、地域別、範囲および予測

エピジェネティクスの市場規模と予測

エピジェネティクス市場規模は、2024年に13億米ドルと評価され、2024年から2031年にかけて13.94%のCAGRで成長し、2031年には37億米ドルに達すると予測されます。エピジェネティクスは、DNA配列の変更を伴わない遺伝的な遺伝子発現の変化を研究する学問です。これらの変化は、DNAメチル化、ヒストン修飾、ノンコーディングRNA分子など、様々な方法によって起こりうる。エピジェネティクスは、開発、細胞分化、環境刺激に対する反応など、多くの生物学的プロセスにおいて重要です。エピジェネティクスは、エピジェネティックな修飾を理解することで新たな治療法につながる可能性のあるがん研究や、エピジェネティックなプロファイリングによって治療戦略の指針となる個別化医療などの分野で新たな応用を見出しています。

エピジェネティクスは、特にCRISPR遺伝子編集やハイスループットシークエンシングのような最先端技術の導入により、かなりの進歩を遂げようとしています。これらの進歩により、エピジェネティクスのランドスケープとそのダイナミックな特徴についての理解が深まり、研究者は複雑な疾患を分子レベルで解明できるようになると思われます。

異常なエピジェネティック変化を修復することを目的としたエピジェネティック治療は、神経疾患や代謝性疾患など、さまざまな疾患に対して興味深い治療法を提供します。エピジェネティクスに対する理解が深まるにつれ、ヘルスケアや治療介入の開発においてますます重要な役割を果たすようになり、よりオーダーメイドで成功する治療への道が開かれると期待されています。

世界のエピジェネティクス市場力学

世界のエピジェネティクス市場を形成している主な市場力学

主な市場促進要因

がん有病率の増加：

がんの世界の有病率の増加は、エピジェネティクス市場の重要な促進要因です。WHOによると、がんによる死者は2020年に約1,000万人に達し、IARCは2040年までに2,840万人が新たにがんに罹患すると予測しており、これは47%の増加です。がん罹患率の増加は、研究者が遺伝子発現の変動に基づくより効果的な標的治療を求めているため、エピジェネティック医薬品と診断の需要を押し上げています。

研究開発投資の増加：

エピジェネティック研究への資金提供の増加が市場拡大の原動力となっています。米国立衛生研究所（NIH）によると、エピジェネティクス研究のための資金は過去10年間で85％急増し、2013年の5億7,300万米ドルから2022年には10億6,000万米ドルに達します。この多額の資金により、エピジェネティクスに基づく医薬品や診断ツールの開発が加速しています。

個別化医療における応用の拡大：

エピジェネティクス市場は個別化医療の動向により成長を遂げています。The tailored Medicine Coalitionの報告によると、FDAが承認した新規医薬品のうち、テーラーメイド医薬品が占める割合は2005年の5%から2018年には25%に増加しました。エピジェネティックバイオマーカーは、個々の患者に合わせて治療を個別化するために不可欠であり、エピジェネティック技術とサービスの需要を促進しています。

主な課題

エピジェネティックなメカニズムの複雑さ：

エピジェネティックな制御には、DNAメチル化、ヒストン修飾、RNA干渉など様々なメカニズムが関与しており、これらはすべて密接に相互作用しています。これらの複雑なシステムを理解することは難しく、標的医薬品の開発を遅らせています。疾患における様々なシステムの正確な機能を解明する必要があるため、研究が妨げられ、新薬の発見や商品化のスピードに影響を及ぼしています。

高い研究開発費：

エピジェネティクスに基づく医薬品や診断薬の開発には高度な技術と知識が必要であり、研究開発コストが高くなります。最先端のシークエンシング技術、バイオインフォマティクスツール、臨床試験にかかる高額な費用は、中小のバイオテクノロジー企業に経済的負担を強います。その結果、技術革新は資金力のある研究機関に限定され、市場拡大が遅れ、新規企業の参入を妨げています。

臨床試験での高い失敗率：

エピジェネティック医薬品の多くは、臨床試験で有効性や安全性を示せず、大幅な減少率を示しています。このような失敗は投資意欲を減退させるだけでなく、費用を増加させ、潜在的な医薬品の承認を遅らせる。高い失敗率は、エピジェネティック経路を実用的な医薬品に変換することの複雑さを反映しており、これが市場の進展を遅らせています。

主要動向：

シーケンス技術の進歩：

次世代シーケンサー（NGS）技術により、エピジェネティックな変化をゲノムレベルで調べる能力が大幅に向上しました。これらの開発により、DNAメチル化やヒストンの変化をより正確に検出できるようになり、より迅速で正確な調査が可能になった。NGSの低コスト化と効率の向上は、個人のエピジェネティック・プロファイルに基づくオーダーメイド医薬品の開発を促進し、エピジェネティクス市場の成長を早めています。

個別化医療への注目の高まり

エピジェネティクスは、個人の遺伝的およびエピジェネティックなプロファイルに適合した治療を可能にするため、個別化医療の重要な要素です。個別化エピジェネティック療法は、がんなどの疾患に関連する特定の遺伝子発現変化を標的とすることができ、治療効果を高めながら悪影響を抑えることができます。ヘルスケア産業がより個別化された治療へとシフトするにつれて、エピジェネティック診断と医薬品に対する需要が増加しています。

加齢とエピジェネティクスへの関心の高まり：

エピジェネティクスは老化研究においてますます重要性を増しており、加齢に伴う遺伝子発現の変化ががんや神経障害を含む様々な疾患の一因であることを示す研究が行われています。世界の人口が高齢化するにつれ、エピジェネティクスの変化が老化プロセスにどのような影響を及ぼすか、また医薬品がこれらの変化を遅らせたり逆転させたりできる可能性を理解することが重視されるようになり、市場の関心と投資が高まっています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 エピジェネティクス市場：製品タイプ別

• キットおよび試薬
• 機器・装置
• サービスとソフトウェア

第5章 エピジェネティクス市場：用途別

• 腫瘍学
• 神経学
• 心臓疾患
• 発生生物学

第6章 エピジェネティクス市場：エンドユーザー別

• 学術・研究機関
• 製薬・バイオテクノロジー企業
• 臨床研究所
• アグリバイオ企業

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Shutterstock, Inc.
• Adobe Inc.
• Getty Images, Inc.
• Pond5, Inc.
• iStock（by Getty Images）
• VideoBlocks
• Storyblocks, Inc.
• Dissolve, Inc.
• Depositphotos, Inc.
• MotionElements Pte. Ltd.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Epigenetics Market Size And Forecast

Epigenetics Market size was valued at USD 1.30 Billion in 2024 and is projected to reach USD 3.70 Billion by 2031 , growing at a CAGR of 13.94% from 2024 to 2031. Epigenetics is the study of heritable changes in gene expression that do not entail modifications to the underlying DNA sequence. These alterations can occur through a variety of methods, including DNA methylation, histone modification, and non-coding RNA molecules, all of which can influence gene function and contribute to phenotypic variability. Epigenetics is important in many biological processes, including development, cellular differentiation, and reactions to environmental stimuli. Epigenetics is finding new applications in sectors such as cancer research, where understanding epigenetic modifications might lead to novel therapeutic methods, and personalized medicine, where epigenetic profiling can guide treatment strategies.

Epigenetics is set for considerable progress, particularly with the incorporation of cutting-edge technologies like CRISPR gene editing and high-throughput sequencing. These advancements will improve our grasp of the epigenetic landscape and its dynamic character, allowing researchers to unravel complicated disorders on a molecular scale.

Epigenetic therapies, which aim to repair aberrant epigenetic alterations, offer intriguing treatment options for a variety of ailments, including neurological disorders and metabolic diseases. As our understanding of epigenetics grows, it is expected to play an increasingly important role in developing healthcare and therapeutic interventions, paving the path for more tailored and successful treatments.

Global Epigenetics Market Dynamics

The key market dynamics that are shaping the global epigenetics market include:

Key Market Drivers:

Increasing Cancer Prevalence:

The increased global prevalence of cancer is a significant driver of the epigenetics market. According to the WHO, cancer killed roughly 10 million people in 2020, and the IARC projects 28.4 million new cases by 2040, a 47% rise. The increase in cancer incidence is driving up demand for epigenetic medicines and diagnostics, as researchers seek more effective, targeted treatments based on gene expression variations.

Rising Investment in Research and Development:

Increased funding for epigenetic research is driving market expansion. According to the National Institutes of Health (NIH), funding for epigenetics research has surged by 85% over the past decade, from $573 million in 2013 to $1.06 billion in 2022. This significant funding has accelerated the development of epigenetic-based medicines and diagnostic tools.

Growing Application in Personalized Medicine:

The epigenetics market is experiencing growth due to the trend towards personalized medicine. The tailored Medicine Coalition reported that tailored medicines accounted for 25% of all new pharmaceuticals approved by the FDA in 2018, up from 5% in 2005. Epigenetic biomarkers are critical for personalizing treatments to individual patients, which drives demand for epigenetic technology and services.

Key Challenges:

Complexity of Epigenetic Mechanisms:

Epigenetic regulation involves a variety of mechanisms, including DNA methylation, histone modification, and RNA interference, all of which interact intimately. Understanding these complicated systems is difficult, delaying the development of targeted medicines. The necessity to determine the precise function of various systems in diseases hampers research, affecting the rate at which new medicines are found and commercialized.

High Research and Development Costs:

Developing epigenetic-based medicines and diagnostics necessitates advanced technology and knowledge, which raises R&D costs. The high expense of cutting-edge sequencing technologies, bioinformatics tools, and clinical trials places a financial burden on smaller biotech enterprises. As a result, innovation is restricted to well-funded institutions, delaying market expansion and preventing the entry of new firms.

High Failure Rate in Clinical Trials:

Many epigenetic medicines fail to show efficacy or safety in clinical trials, owing to significant attrition rates. These failures not only discourage investment but also raise expenses and slow the approval of potential medicines. The high failure rate reflects the complexities of converting epigenetic pathways into practical medicines, which has slowed market advancement.

Key Trends:

Advancements in Sequencing Technologies:

Next-generation sequencing (NGS) technologies have considerably increased the ability to examine epigenetic changes at the genome-wide level. These developments enable more precise detection of DNA methylation and histone changes, resulting in faster and more accurate research. The lower cost and better efficiency of NGS are driving the development of tailored medicines based on an individual's epigenetic profile, hastening the growth of the epigenetics market.

Growing Focus on Personalized Medicine:

Epigenetics is an important component of personalized medicine as it allows for therapies that are matched to individual genetic and epigenetic profiles. Personalized epigenetic therapy can target specific gene expression alterations associated with diseases such as cancer, increasing treatment efficacy while lowering negative effects. As the healthcare industry shifts toward more personalized treatment, demand for epigenetic diagnostics and medicines is increasing.

Growing Interest in Aging and Epigenetics:

Epigenetics has grown increasingly important in aging research, with studies indicating that age-related changes in gene expression contribute to a variety of diseases, including cancer and neurological disorders. As the world's population ages, there is a rising emphasis on understanding how epigenetic modifications affect aging processes and how medicines may be able to slow or reverse these changes, generating market interest and investment.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Epigenetics Market Regional Analysis

Here is a more detailed regional analysis of the global epigenetics market:

North America:

North America continues to dominate the global epigenetics market, owing to considerable research investments and a high prevalence of epigenetic illnesses, particularly cancer. The NIH's funding for epigenetics research in the US has increased by 85%, from $573 million in 2013 to $1.06 billion in 2022. This initiative demonstrates the region's commitment to advancing epigenetic medicines and diagnostics. With roughly 2 million new cancer cases projected in the United States by 2023, demand for epigenetic-based treatments is increasing, as epigenetic modifications play an important role in cancer formation.

The region's robust biotechnology and pharmaceutical industries also drive innovation. In 2018, the US bioscience industry employed 1.87 million workers, allowing for the quick commercialization of epigenetic discoveries. The FDA's approval of many epigenetic treatments contributes to market growth. North America's early embrace of advanced technology such as next-generation sequencing, hastens epigenetics research and ensures its market dominance.

Asia Pacific:

The Asia Pacific epigenetics market is expanding rapidly, fueled by increased research funding and the rising prevalence of diseases with epigenetic connections, such as cancer. Regional R&D spending is expected to exceed $1.2 trillion by 2025, with a major amount dedicated to life sciences and biotechnology. Countries like China, which are predicted to see a huge increase in cancer incidence (from 4.57 million in 2020 to 6.67 million by 2040), are driving demand for epigenetic-based diagnostics and cures. This increase in investment and illness load is hastening the region's market expansion.

Furthermore, aging populations, notably in Japan, and supportive government programs, such as India's Genome India Project, are accelerating epigenetics research. Rising disposable income in the region, which has resulted in higher healthcare spending, is pushing up demand for innovative medical technologies such as epigenetic tools. The increased usage of next-generation sequencing technology, projected to reach $5.6 billion by 2026, is permitting more complex epigenetic investigations, establishing Asia Pacific as a significant player in the global epigenetics market.

Global Epigenetics Market: Segmentation Analysis

The Global Epigenetics Market is Segmented on the basis of Product Type, Application, End-User, And Geography.

Epigenetics Market, By Product Type

• Kits and Reagents
• Instruments and Equipment
• Enzymes

Based on Product Type, the market is bifurcated into Kits and Reagents, Instruments and Equipment, and Enzymes. The Kits and Reagents category is dominant due to their essential significance in research and diagnosis, since they are commonly employed for DNA methylation, histone modification, and chromatin accessibility studies. The fastest-growing area is Enzymes, which is being driven by rising demand for enzymes such as DNA methyltransferases and histone deacetylases in drug discovery and personalized medicine, particularly in cancer research and therapeutic development.

Epigenetics Market, By Application

• Oncology
• Neurology
• Developmental Biology

Based on Application, the market is segmented into Oncology, Neurology, and Developmental Biology. Oncology is the dominant segment, owing to the high frequency of cancer and the crucial significance of epigenetic changes in cancer genesis, diagnosis, and treatment. Epigenetic treatments, which target DNA methylation and histone modification, are commonly used in oncology. Neurology is the fastest-growing category, with research into epigenetic aspects in neurodegenerative disorders such as Alzheimer's and Parkinson's gaining traction, opening up new diagnostic and therapeutic possibilities.

Epigenetics Market, By End-User

• Academic Research
• Pharmaceutical and Biotechnology Companies
• Clinical Laboratories
• Government Research Institutes

Based on End-User, the market is segmented into Academic Research, Pharmaceutical and Biotechnology Companies, Clinical Laboratories, and Government Research Institutes. Pharmaceuticals and Biotechnology Companies dominate due to their essential role in creating epigenetic-based medicines, particularly for cancer and other chronic diseases. These companies make significant investments in research and development to create novel medications and diagnostic technologies. Academic Research is the fastest-growing category, driven by rising funding for fundamental and translational epigenetics research as universities and research institutes investigate new therapeutic targets and personalized medicine applications.

Epigenetics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of geographical analysis, the Global Epigenetics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America has been the dominating region in the epigenetics market due to its strong research infrastructure, the presence of large firms, and the well-developed regulatory environment. The Asia Pacific region is witnessing the quickest development, owing to increased research spending, increased knowledge of epigenetics, favorable government regulations, and rising disposable income.

Key Players

• The "Global Epigenetics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Shutterstock, Inc., Adobe Inc., Getty Images, Inc., Pond5, Inc., iStock (by Getty Images), VideoBlocks, Storyblocks, Inc., Dissolve, Inc., Depositphotos, Inc., and MotionElements Pte. Ltd.
• The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Epigenetics Market Recent Developments
• In January 2024, Moonwalk Biosciences, a pioneering genomic medicine startup focused on the creation of precise epigenetic therapeutics, raised USD 57 million in seed and Series A funding. Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures were among the major investors who donated investments.
• In February 2024, PharmaKure, a clinical-stage pharmaceutical company, announced a new epigenetics relationship with Sheffield Hallam University. This partnership will focus on 'gene-based environmental biomarkers,' also known as epigenetic markers, to estimate risk scores for Alzheimer's disease.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Epigenetics Market, By Product Type

• Kits and Reagents
• Instruments and Equipment
• Services and Software

5. Epigenetics Market, By Application

• Oncology
• Neurology
• Heart Disease
• Developmental Biology

6. Epigenetics Market, By End-User

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Clinical Laboratories
• Agri-Biotech Companies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Shutterstock, Inc.
• Adobe Inc.
• Getty Images, Inc.
• Pond5, Inc.
• iStock (by Getty Images)
• VideoBlocks
• Storyblocks, Inc.
• Dissolve, Inc.
• Depositphotos, Inc.
• MotionElements Pte. Ltd.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References